Immunomolecular Therapeutics

IMT is the initial organization to focus on the underlying cause of autoimmunity using therapeutic design aimed at HLA variations recognized to present significant disease susceptibility. The firm's platform constructs drug compounds to specifically obstruct an HLA protein in a particular autoimmune disorder, introducing a new model in pharmaceutical development. Our oral therapy drug development employs a distinct method to balance the binding site(s) affinity to HLA for achieving obstruction while safeguarding the innate immune response against pathogens conferred by the HLA proteins.